ClinicaliQ Trial Snapshot
- A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Recruiting • Phase III • Oncology • NCT06417814.
- What is being tested: Dato-DXd (a novel antibody-drug conjugate) as monotherapy or combined with osimertinib versus standard platinum-based chemotherapy, with primary endpoint of progression-free survival in EGFR-mutated advanced lung cancer.
- Patient eligibility overview: Adults with EGFR-mutated locally advanced or metastatic non-small cell lung cancer, representing a treatment-Phase IIIïve or previously treated population meeting specific molecular and disease stage criteria.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Eligibility Snapshot
- : * Histologically or cytologically confirmed non-squamous NSCLC. * Must have evidence of documented pre-existing EGFRm information (EGFRm known to be associated with (epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKis] sensitivity [Ex19del, L858R, G719X, S768I, or L861Q], either alone or in combination with other EGFR mutations, which may include T790M). * Documented extra-cranial radiologic progression on prior osimertinib monotherapy (as most recent line of treatment) in the adjuvant, locally advanced, or metastatic setting. * Less than or equal to (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.